GSK: positive results for investigational anti-tuberculosis
(CercleFinance.com) - GSK today announced positive results from a Phase IIa study demonstrating that GSK3036656, an investigational first-in-class anti-tuberculosis agent, was "well tolerated" and showed early bactericidal activity when administered orally at a low dose after 14 days of treatment.
This data can be used as a basis for Phase IIb/c studies, with the aim of contributing to shorter, simpler and better tolerated treatment regimens for TB patients.
GSK says that these results demonstrate the potential for GSK3036656 to be a component of simpler treatment regimens in the future, which may help to combat the TB epidemic.
Copyright (c) 2022 CercleFinance.com. All rights reserved.